Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study
Krebs, Matthew G Spira, A. I. Cho, B. C. Besse, B. Goldman, J. W. Janne, P. A. Ma, Z. Y. Mansfield, A. S. Minchom, A. R. Ou, S. H. I.
Krebs, Matthew G
Spira, A. I.
Cho, B. C.
Besse, B.
Goldman, J. W.
Janne, P. A.
Ma, Z. Y.
Mansfield, A. S.
Minchom, A. R.
Ou, S. H. I.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Krebs M, Spira AI, Cho BC, Besse B, Goldman JW, Janne PA, et al. Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680302199.